within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB10_Mobocertinib;

model Mobocertinib
  extends Pharmacolibrary.Drugs.ATC.L.L01EB10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EB10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mobocertinib is an oral tyrosine kinase inhibitor (TKI) that specifically targets epidermal growth factor receptor (EGFR) exon 20 insertion mutations, which are found in a subset of non-small cell lung cancer (NSCLC) patients. Mobocertinib is approved for the treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 20 insertion mutations and who have progressed on or after platinum-based chemotherapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with locally advanced or metastatic NSCLC following repeated oral administration of mobocertinib 160 mg once daily.</p><h4>References</h4><ol><li><p>Hanley, MJ, et al., &amp; Gupta, N (2024). A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [. <i>Investigational new drugs</i> 42(4) 343–352. DOI:<a href=\"https://doi.org/10.1007/s10637-024-01446-y\">10.1007/s10637-024-01446-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38789848/\">https://pubmed.ncbi.nlm.nih.gov/38789848</a></p></li><li><p>Zhang, S, et al., &amp; Gupta, N (2021). Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products. <i>Clinical pharmacology in drug development</i> 10(9) 1028–1043. DOI:<a href=\"https://doi.org/10.1002/cpdd.951\">10.1002/cpdd.951</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34118178/\">https://pubmed.ncbi.nlm.nih.gov/34118178</a></p></li><li><p>Zhang, S, et al., &amp; Gupta, N (2021). Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 10(9) 1044–1053. DOI:<a href=\"https://doi.org/10.1002/cpdd.967\">10.1002/cpdd.967</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34145979/\">https://pubmed.ncbi.nlm.nih.gov/34145979</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Mobocertinib;
